Coherus Oncology, Inc. — fact timeline

Coherus Oncology, Inc. engaged PricewaterhouseCoopers LLP as its auditor.

“On June 12, 2026, the Audit Committee of the Board of Directors of the Company selected PricewaterhouseCoopers LLP (“PwC”) to be appointed to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures.”

Coherus Oncology, Inc. dismissed Ernst & Young LLP as its auditor.

“On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with dismissal effective as of such date.”

Coherus Oncology, Inc. shareholders approved Approval of increase in number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan at the 2026-05-27 meeting.

“The Company’s stockholders approved an increase in the number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan.”

Coherus Oncology, Inc. shareholders approved Approval of reduction in exercise price of certain outstanding stock options at the 2026-05-29 meeting.

“The Company’s stockholders approved the reduction in the exercise price of certain outstanding stock options.”

Coherus Oncology, Inc. shareholders approved Advisory vote to approve compensation of named executive officers (Say-on-Pay) at the 2026-05-27 meeting.

“The Company’s stockholders approved a non-binding, advisory resolution to approve the compensation of the Company’s named executive officers (a “Say-on-Pay” vote).”

Coherus Oncology, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-27 meeting.

“The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”

Coherus Oncology, Inc. shareholders approved Election of Class III directors at the 2026-05-27 meeting.

“The Company’s stockholders elected by a majority of votes cast each of the Class III director nominees below, Dennis M. Lanfear and Mats L. Wahlström, to the Board of Directors of the Company to hold office until the 2029 annual meeting of stockholders or until their successors are elected.”

Coherus Oncology, Inc. reported financial results for first quarter 2026.

“On May 11, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026.”

Coherus Oncology, Inc. reported the years ended December 31, 2025 results: revenue $42.2 million.

“Net revenue from continuing operations was $12.7 million and $7.7 million during the three months ended December 31, 2025 and 2024, respectively, and $42.2 million and $26.4 million during the years ended December 31, 2025 and 2024, respectively.”

Coherus Oncology, Inc. reported the three months ended December 31, 2025 results: revenue $12.7 million.

“Net revenue from continuing operations was $12.7 million and $7.7 million during the three months ended December 31, 2025 and 2024, respectively, and $42.2 million and $26.4 million during the years ended December 31, 2025 and 2024, respectively.”

Coherus Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1).The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market. ​ In accordance with Nasdaq Listi”

Mark D. Stolper departed as Director at Coherus Oncology, Inc..

“On April 22, 2025, Mark D. Stolper, a member of the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), notified the Board of his intention not to stand for re-election to the Board for an additional three-year term at the Company's 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).”

Paul Reider resigned as Chief Commercial Officer at Coherus Oncology, Inc..

“Paul Reider notified Coherus BioSciences, Inc. (the “Company”) on April 16, 2025 of his resignation as Chief Commercial Officer and employee of the Company effective on April 30, 2025 in order to pursue other opportunities”

Coherus Oncology, Inc. completed a disposition involving Intas Pharmaceuticals Ltd. for $483.4 million in cash (closed 2025-04-11).

“On April 11, 2025 (the “Closing Date”), the Company completed the divestiture of the Business (the “UDENYCA Disposition”) to Intas for upfront, all-cash consideration of $483.4 million in cash, inclusive of $118.4 million for UDENYCA product inventory.”

Bryan McMichael was appointed as Chief Financial Officer at Coherus Oncology, Inc..

“On August 7, 2024, the Company’s board of directors appointed Bryan McMichael, age 46, the Company’s current Interim Chief Financial Officer, Executive Vice President, Accounting, Corporate Controller, to serve as the Company’s Chief Financial Officer effective August 1, 2024.”

Coherus Oncology, Inc. completed a disposition involving Hong Kong King-Friend Industrial Company Ltd. for upfront, all-cash consideration of $40.0 million (closed 2024-06-26).

“commitments, but not including certain identified excluded assets and excluded liabilities (collectively, the “YUSIMRY Disposition”) for upfront, all-cash consideration of $40.0 million paid on June 26, 2024. ​ The Purchase Agreement also provides for indemnification rights related to breaches of each party’s representations, warranties, covenants and certain”

Rita A. Karachun was appointed as Class II Director at Coherus Oncology, Inc..

“the vacancy on the Board created by such increase would be filled by the appointment of Rita A. Karachun, with such appointment becoming effective upon the receipt of certain confirmations, which were received May 31, 2024.”

Coherus Oncology, Inc. incurred term loan of $38.7 million with Ankura Trust Company, LLC at 8.00% per annum, plus a three month SOFR rate maturing May 8, 2029.

“On May 8, 2024, Coherus BioSciences, Inc., a Delaware corporation (the “Company”), entered into a senior secured term loan facility of up to $38.7 million (the “Term Loan”), all to be funded on May 8, 2024 (the “Effective Date”), with Ankura Trust Company, LLC, as administrative agent”

Coherus Oncology, Inc. reported the quarter ended March 31, 2024 results: revenue $77.1 million, net income $102.9 million, EPS $0.83 per share on a diluted basis.

“reference in such a filing. --- EX-99.1 (EX-99.1) --- ​ ​ ​ Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update ​ – Net revenue of $77.1 million in Q1 2024 – ​ – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – ​ – New debt and royalty financing replaces $75 million term loan, with debt”

Coherus Oncology, Inc. terminated Prior Loan Agreement valued at $75 million (effective 2024-05-08).

“In connection with the entry into the Loan Agreement, on the Effective Date, the Company repaid in full all outstanding indebtedness and terminated all commitments under the Prior Loan Agreement, the material terms of which have been disclosed previously.”

Coherus Oncology, Inc. entered into Revenue Purchase and Sale Agreement with Coduet Royalty Holdings, LLC, as administrative agent and each buyer named in an annex thereto valued at $37.5 million (effective 2024-05-08).

“On May 8, 2024, the Company entered into a revenue participation right purchase and sale agreement (the “Revenue Purchase and Sale Agreement”) with Coduet Royalty Holdings, LLC, as administrative agent and each buyer named in an annex thereto (collectively, the “Purchaser”).”

Coherus Oncology, Inc. entered into Loan Agreement with Ankura Trust Company, LLC, as administrative agent, and the lenders signatory thereto valued at $38.7 million (effective 2024-05-08).

“On May 8, 2024, Coherus BioSciences, Inc., a Delaware corporation (the “Company”), entered into a senior secured term loan facility of up to $38.7 million (the “Term Loan”), all to be funded on May 8, 2024 (the “Effective Date”), with Ankura Trust Company, LLC, as administrative agent (in such capacity, the “Agent”), and the lenders signatory thereto (collectively, the “Lenders”).”

Coherus Oncology, Inc. reported financial results for fiscal year ended December 31, 2023.

“On March 13, 2024, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the fiscal year ended December 31, 2023.”

Coherus Oncology, Inc. completed a disposition involving Sandoz Inc. for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets (closed 2024-03-01).

“On March 1, 2024, the Company completed the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Purchaser (the “Disposition”) for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets.”

Coherus Oncology, Inc. amended term loan with Biopharma Credit PLC, BPCR Limited Partnership, Biopharma Credit Investments V (MASTER) LP.

“on February 5, 2024, the Company, as borrower and on behalf of itself and certain of its subsidiaries, entered into a Consent, Partial Release and Third Amendment to Loan Agreement (the “Consent and Amendment”) with Biopharma Credit PLC, a public limited company incorporated under the laws of England and Wales, as collateral agent (the “Collateral Agent”), BPCR Limited Partnership, a limited partnership established under the laws of England and Wales, as a lender (“BPCR”), and Biopharma Credit Investments V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a lender, and together with as BPCR, each, a “Lender” and collectively, the “Lenders”), pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the Existing Loan Agreement and the other loan documents in connection therewith, and the partie”

Georgia Erbez was appointed as Class III Director at Coherus Oncology, Inc..

“On February 20, 2024, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), increased the size of the Board from nine directors to ten directors and approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Georgia Erbez to serve as a Class III director to fill the vacancy created by such increase.”

Coherus Oncology, Inc. amended Consent, Partial Release and Third Amendment to Loan Agreement with Biopharma Credit PLC, BPCR Limited Partnership, Biopharma Credit Investments V (MASTER) LP valued at $175,000,000 (effective 2024-02-05).

“On February 5, 2024, Coherus BioSciences, Inc. (the “Company”), as borrower and on behalf of itself and certain of its subsidiaries, entered into a Consent, Partial Release and Third Amendment to Loan Agreement (the “Consent and Amendment”) with Biopharma Credit PLC, a public limited company incorporated under the laws of England and Wales, as collateral agent (the “Collateral Agent”), BPCR Limited Partnership, a limited partnership established under the laws of England and Wales, as a lender (“BPCR”), and Biopharma Credit Investments V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a lender, and together with as BPCR, each, a “Lender” and collectively, the “Lenders”), pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the Existing Loan Agreement and the other loan documents in connec”

Coherus Oncology, Inc. reported preliminary financial results for fiscal year ended December 31, 2023.

“On January 10, 2024, Coherus BioSciences, Inc. (the “Company”) will present its preliminary unaudited revenue for the fiscal year ended December 31, 2023 in a public webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the preliminary financial information included in such presentation is furnished as Exhibit 99.1 to this report and will be available on the Company’s investor relations website at www.investors.coherus.com as previously announced.”

Bryan McMichael was appointed as Interim Chief Financial Officer and Principal Financial Officer at Coherus Oncology, Inc..

“The Board of Directors of the Company appointed Bryan McMichael, age 45, to serve as the Company’s Interim Chief Financial Officer and Principal Financial Officer effective December 8, 2023.”

McDavid Stilwell resigned as Chief Financial Officer, Principal Financial Officer at Coherus Oncology, Inc..

“McDavid Stilwell notified the Company on December 7, 2023 of his resignation as Chief Financial Officer, Principal Financial Officer and employee of the Company in order to pursue other opportunities, in each case to be effective on December 31, 2023.”

McDavid Stilwell resigned as Chief Financial Officer at Coherus Oncology, Inc..

“McDavid Stilwell notified the Company on December 7, 2023 of his resignation as Chief Financial Officer, Principal Financial Officer and employee of the Company in order to pursue other opportunities, in each case to be effective on December 31, 2023.”

Coherus Oncology, Inc. reported financial results for third quarter ended September 30, 2023.

“On November 6, 2023, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2023.”

Coherus Oncology, Inc. amended Sixth Amendment with Hudson 333 Twin Dolphin Plaza, LLC (effective 2023-10-24).

“(the “Company”) has been a party to an existing Office Lease (as amended, the “Lease”) with Hudson 333 Twin Dolphin Plaza, LLC (the “Landlord”), under which the Company leases approximately 47,789 square feet of office space located at 333 Twin Dolphin Drive, Redwood City, California (the “Currently Existing Premises”) for the Company’s principal executive offices with an expiration date of September 30, 2024 (the “Extended Expiration Date”).”

Coherus Oncology, Inc. completed an acquisition involving Surface Oncology, Inc. for approximately $66.9 million (closed 2023-09-08).

“Surface employee equity awards (which exchange ratio was calculated based on a $5.2831 per share price of Coherus common stock) for a total value equal to approximately $66.9 million, the sum of $40 million plus Surface’s net cash at closing of the transaction of $26.9 million. Surface shareholders also received contingent value rights (CVRs) for 70% of”

Coherus Oncology, Inc. reported the second quarter ended June 30, 2023 results: revenue $58.7 million.

“Net revenue was $58.7 million during the three months ended June 30, 2023”

Michael Ryan was appointed as Class III director at Coherus Oncology, Inc..

“On July 18, 2023, the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), approved, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Michael Ryan, Pharm.D., to serve as a Class III director to fill a vacancy on the Board.”

Coherus Oncology, Inc. entered into Agreement and Plan of Merger with Surface Oncology, Inc. (effective 2023-06-15).

“On June 15, 2023, Coherus BioSciences, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Crimson Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub I ”), Crimson Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“ Merger Sub II ” and together with Merger Sub I, the “ Merger Subs ”), and Surface Oncology, Inc., a Delaware corporation (“ Surface ”).”

Coherus Oncology, Inc. shareholders approved Non-binding advisory resolution to approve the compensation of the Company's named executive officers (Say-on-Pay) at the 2023-06-07 meeting.

“Proposal 3. The Company’s stockholders approved a non-binding, advisory resolution to approve the compensation of the Company’s named executive officers (a “Say-on-Pay” vote). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BROKER FOR AGAINST ABSTAIN NON-VOTES 55,379,513 ​ 3,233,870 ​ 189,968 ​ 7,102,965”

Coherus Oncology, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.

“Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BROKER FOR AGAINST ABSTAIN NON-VOTES 65,375,866 ​ 434,987 ​ 95,463 ​ 0”

Coherus Oncology, Inc. shareholders approved Election of Class III Directors: Dennis M. Lanfear and Mats L. Wahlström at the 2023-06-07 meeting.

“Proposal 1. The Company’s stockholders elected by a majority of votes cast both of the Class III director nominees below, Dennis M. Lanfear and Mats L. Wahlström, to the Board to hold office until the 2026 annual meeting of stockholders or until their successors are elected. ​ ​ ​ ​ ​ ​ BROKER ​ NOMINEE ​ FOR WITHHELD NON- ​ VOTES ​ Dennis M. Lanfear 57,378,374 ​ 1,424,977 ​ 7,102,965 ​ ​ Mats L. Wahlström 42,646,152 ​ 16,157,199 ​ 7,102,965”

Coherus Oncology, Inc. amended Amendment No. 1 to Sales Agreement with Cowen and Company, LLC valued at $86.25 million (effective 2023-05-15).

“reduced the amount of shares that could be issued and sold pursuant to its “at-the-market” program (“ATM”) with Cowen and Company, LLC (“Cowen”) in an amount equal to $86.25 million.”

Coherus Oncology, Inc. updated its fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).

“On March 6, 2023, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022.”

Coherus Oncology, Inc. announced a restructuring with charges of approximately $3.4 million (approximately 60 full-time and part-time employees).

“On March 3, 2023, the Company committed to a plan to reduce its workforce (the “Plan”) by approximately 20% to focus resources on strategic priorities including the commercialization of its diversified product portfolio and development of innovative immuno-oncology product candidates. The Company initiated a reduction in force impacting approximately 60 full-time and part-time employees effective March 10, 2023 for most employees. One-time restructuring charges associated with the reduction in force are expected to be approximately $3.4 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits.”

Vladimir Vexler resigned as Chief Scientific Officer at Coherus Oncology, Inc..

“On March 2, 2023, Vladimir Vexler, Ph.D., resigned from his role as Chief Scientific Officer of the Company, effective March 10, 2023, unless the effective date is extended to March 31, 2023 at Dr. Vexler’s option.”

Coherus Oncology, Inc. reported third quarter ended September 30, 2022 results: revenue $45.4 million, net income Net loss of $86.7 million, or $(1.11) per share, EPS $(1.11) per share.

“Net revenue, consisting primarily of net sales of UDENYCA®, was $45.4 million”

McDavid Stilwell changed role as Principal Accounting Officer at Coherus Oncology, Inc..

“Mr. Stilwell continues his service to the Company as the Company’s Chief Financial Officer and Principal Financial Officer but will no longer serve as Principal Accounting Officer effective September 7, 2022.”

Bryan McMichael was appointed as Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer at Coherus Oncology, Inc..

“On September 9, 2022, Coherus BioSciences, Inc. (the “Company”) announced the appointment of Bryan McMichael, age 44, as Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer, effective September 7, 2022.”

Jill O'Donnell-Tormey was appointed as Director at Coherus Oncology, Inc..

“the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the authorized number of directors that can serve on the Board from seven to eight directors and, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), resolved that the vacancy on the Board created by such increase would be filled with the appointment of Jill O’Donnell-Tormey, Ph.D. effective May 18, 2022.”

Charles Newton was appointed as Class I director at Coherus Oncology, Inc..

“On May 4, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), a vacancy on the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) was filled with the appointment of Charles Newton.”

James I. Healy resigned as Director at Coherus Oncology, Inc..

“On February 4, 2022, James I. Healy, M.D., Ph.D. resigned from the Board of the Company, effective immediately upon notice of his resignation.”